In UK military veterans (P) the remotely delivered Fast Imagery Reversal Script for Trauma release Protocol (I), compared to waiting list control (C) is clinically and statistically effective in reducing post-traumatic stress disorder symptoms by the minimal clinically important difference (O) at 20 weeks (T)

开始日期2025-11-01

申办/合作机构

King's College London

ITMCTR2024000148

/ SuspendedN/AIIT

Clinical study on the effect of Sublumbilical camp under the needle knife release on neurogenic bladder function after spinal cord injury

开始日期2024-11-01

申办/合作机构-

CTRI/2024/10/075516

/ Not yet recruitingN/A

Influence of Myofascial Release and Remote Myofascial Release on Gait and Muscle Activation In Asymptomatic Hamstring Muscle Tightness - NIL

开始日期2024-10-28

申办/合作机构

Jamia Millia Islamia

100 项与美喹他嗪相关的临床结果

登录后查看更多信息

100 项与美喹他嗪相关的转化医学

登录后查看更多信息

100 项与美喹他嗪相关的专利（医药）

登录后查看更多信息

279

项与美喹他嗪相关的文献（医药）

2025-07-16·BIOLOGICAL & PHARMACEUTICAL BULLETIN

Second-Generation H<sub>1</sub>-Receptor Antagonists, Mequitazine, Azelastine and Desloratadine Activate Caspase-8, Caspase-3, and Gasdermin E and Induce Cell Death Showing Pyroptotic-Like Features in Macrophages at Excessively High Concentrations

Article

作者: Ito, Akane ; Nakajima, Mitsunari ; Sawamoto, Atsushi ; Okuyama, Satoshi

Histamine H₁ receptor (H₁R) is expressed in various cells, including neurons, smooth muscle cells, hepatocytes, T and B cells, neutrophils, dendritic cells, monocytes, and macrophages. Antagonists that target the H₁R are used to relieve the symptoms of allergy and inflammation. Here, we examined the inflammation-modulating and cell death-inducing effects of 10 second-generation H₁R antagonists on mouse intraperitoneal macrophages, which include ketotifen, mequitazine, azelastine, oxatomide, epinastine, bepotastine, fexofenadine, loratadine, levocetirizine, and desloratadine, to assess an anticipated adverse reaction. Three of these antagonists, namely, mequitazine, azelastine, and desloratadine, induced the secretion of interleukin-1α (IL-1α), a marker of pyroptosis and an inflammatory cytokine, from the macrophages at excessively high concentrations, while reducing the secretion of another inflammatory cytokine, IL-6. We found that the macrophages treated with the 3 antagonists showed pyroptotic-like, but not apoptotic-like, morphology and died. Western blotting analysis revealed that caspase-8, caspase-3, and gasdermin E (GSDME), but not gasdermin D, were cleaved and activated in the macrophages. These results suggest that second-generation H₁R antagonists such as mequitazine, azelastine, and desloratadine induce pyroptotic-like cell death accompanied by caspase-8, caspase-3, and GSDME activation in macrophages.

2024-11-04·CHEMISTRY-A EUROPEAN JOURNAL

Overriding Cage Effect in Electron Donor‐Acceptor Photoactivation of Diaryliodonium Reagents: Synthesis of Chalcogenides

Article

作者: Lisa Roy ; Sanat Kumar Mahapatra ; Sandip Murarka ; Sushanta Kumar Parida ; Prahallad Meher

Abstract:

In recent times, diaryliodonium reagents (DAIRs) have witnessed a resurgence as arylating reagents, especially under photoinduced conditions. However, reactions proceeding through electron donor‐acceptor (EDA) complex formation with DAIRs are restricted to electron‐rich reacting partners serving as donors due to the well‐known cage effect. We discovered a practical and high‐yielding visible‐light‐induced EDA platform to generate aryl radicals from the corresponding DAIRs and use them to synthesize key chalcogenides. In this process, an array of DAIRs and dichalcogenides react in the presence of 1,4 diazabicyclo[2.2.2]octane (DABCO) as a cheap and readily available donor, furnishing a variety of di(hetero)aryl and aryl/alkyl chalcogenides in good yields. The method is scalable, features a broad scope with good yields, and operates under open‐to‐air conditions. The photoinduced chalcogenation technology is suitable for late‐stage functionalizations and disulfide bioconjugations and facilitates access to biologically relevant thioesters, dithiocarbamates, sulfoximines, and sulfones. Moreover, the method applies to synthesizing diverse pharmaceuticals, such as vortioxetine, promazine, mequitazine, and dapsone, under amenable conditions.

2024-07-01·JOURNAL OF FORENSIC SCIENCES

Analysis of unknown (unlabeled/mislabeled) drug products for active pharmaceutical ingredients and related substances by an international mail facility satellite laboratory equipped with rapid screening devices

Article

作者: LaGarde, Donna ; Sterling, Megan E. ; Boyd, Brian ; Howe, Gregory ; Lanzarotta, Adam ; Kern, Sara ; Griffin, Kelsey M. ; Kimani, Martin ; Hudson‐Davis, Morgan ; Gonzalez Illan, Fernando ; Thatcher, Michael ; Batson, JaCinta ; Patel, Anvi ; Arrecis, Julio ; Wetherby, Anthony E. ; Altaf, Muhammad ; Collins, Melissa ; Lorenz, Lisa ; Reimer, Allison M. ; Morales‐Garcia, Flavia ; Laguerre, David ; Loh, Mark

Abstract:

Two chemists employed a three‐device rapid screening “toolkit” consisting of a handheld Raman spectrometer, transportable mass spectrometer, and portable Fourier transform infrared (FT‐IR) spectrometer at an international mail facility (IMF) satellite laboratory to examine unknown (unlabeled/mislabeled) products for the presence of active pharmaceutical ingredients (APIs). Phase I of this project previously demonstrated that this toolkit was the most effective collection of instruments for identifying APIs in product types collected at IMFs during a nationwide mail blitz and Phase II of this project previously demonstrated that results generated using the toolkit during a satellite laboratory pilot program were as reliable as those generated by a full‐service library when two or more of these instruments identify an API. This study (Phase III) described the results of the satellite laboratory toolkit during production mode and encompassed the period ranging from June 2021 through December 2022. During this study, a total of 858 products were examined on‐site at the IMF. The satellite laboratory yielded conclusive results for 726 (84.6%) products, which were used to support regulatory action, and identified 132 (15.4%) products that required additional full‐service laboratory analyses due to inconclusive results. The satellite and full‐service laboratory verified/confirmed at least one API/related substance in 617 (71.9%) products. A total of 709 APIs/related substances were found in the 617 products, and 202 of these 709 compounds were unique/different. Overall, during Phases I through III of this program, 350 different substances have been identified in products collected at IMFs.

303

项与美喹他嗪相关的新闻（医药）

2024-12-05

·药渡

眼科CXO第二篇 | 温敏凝胶载药系统助力眼科产业提质创新

一眼科CXO第二篇〡温敏凝胶载药系统助力眼科产业提质创新上期文章，我们与大家分享了眼科CXO第一篇《纳米载药技术助力眼科产业提质创新》，介绍了眼科领域纳米颗粒-多聚体载体技术在药物动力学方面表现出优于传统剂型的诸多优势。本期文章，我们探讨《温敏凝胶载药系统之原位凝胶技术》在眼科领域的应用。在临床上，眼科药品90%为局部给药方式，非侵入载药系统，用于治疗眼部感染、青光眼、白内障、炎症、过敏、干眼等[1]。眼部生物屏障限制药物进入[2]，加上流泪，鼻抽吸，眨眼等保护机制，滴入药液从角膜前区域会迅速消除[3]。通过增加剂量，重复多次给药则会加重副作用，降低依从性[4]。眼科原位凝胶是一种“刺激-敏感”载药系统，通过制备对眼部温度，pH值，离子敏感凝胶[4]达到增加药物在角膜前驻留时间，提高渗透性提高药物生物利用度，是一种“smart”载药系统。原位凝胶具有如下特征：1.对眼部温度，pH值或离子等环境敏感，具有生物相容性和无刺激性[5]；2.与眼部黏附分2个阶段，首先和滴眼液一样以液体形式，无侵入性与眼部接触，随环境改变黏附在眼部，不受鼻抽吸影响持续释放药物，时间最长可达24小时[6]。与眼膏相比无刺激性，灼热感，视物模糊等情形发生[5]，与混悬液相比具有可预测的一致性和生物等效性[1]。目前国外对温度敏感型原位凝胶研究比较成熟，研发管线涉及到青光眼、抗感染、抗病毒、抗真菌等，前期研究显示，温度敏感型凝胶对眼部无刺激，相容性和总体安全性良好。凝胶载药系统分为天然凝胶（如纤维素衍生物）和合成凝胶（如泊洛沙姆），温敏型原位凝胶最常用泊洛沙姆，具备优秀药物释放特性，低毒性，以及与辅料和药物相容性[6]。汇恩兰德作为专业滴眼液生产基地，深耕眼科赛道十余年，已打造滴眼液CMO/CDMO一站式服务平台。在市场多样化需求下，做好CXO高端服务离不开新质生产力驱动，汇恩兰德现着力打造高端眼用制剂三大技术平台：纳米微乳、原位凝胶、抗氧技术，旨在激烈的市场“内卷”当下，为MAH提供差异化服务，共创可持续发展。二专业眼科用药品生产基地单剂量滴眼液生产线【灌装量】0.4ml~1.0ml 【产能】7000万支/年【标准】新版GMP标准 ★不含防腐剂，安全性好单剂量滴眼液生产线【灌装量】0.2ml~0.8ml 【产能】1.5亿支/年【标准】新版GMP标准 ★不含防腐剂，安全性好多剂量滴眼液生产线【灌装量】5.0ml~10ml 【产能】3500万支/年【标准】新版GMP标准 ★BFS工艺:提供更高级别的无菌保障眼用冲洗液生产线【灌装量】500ml 【产能】200万袋/年【标准】新版GMP标准 ★终灭，软袋：临床使用更加安全方便三生产、检验设施设备四提供服务、联系方式 ❖滴眼液临床及注册样品的委托生产（CMO）提供滴眼液临床样品及注册申报样品的委托加工 ❖MAH产品委托生产承接药品上市许可持有人的滴眼液品种委托生产 ❖滴眼液委托研发及商业化生产(CDMO) 提供滴眼液品种的研发、注册及商业化委托生产 ❖技术转让(License-In/Out) 受让或出让在研及已获批的自主滴眼液品种 ❖生产线定制化服务按照客户需求提供定制化生产专线服务联系方式生产企业：北京汇恩兰德制药有限公司地址：北京市通州区靓丽五街3号院7号楼电话：010-5633-9580,9584 网站：www.huonland.com 参考文献： 1. Jumelle, C et al. J.Control. Release 2020, 321, 1–22. 2. Pandey, M.et al.J.Pharmaceutics 2021, 13, 1 3. Al-Kinani, A.A.et al. J.Rev. 2018, 126, 113–126. 4. Suri, R.et al. J.Technol. 2020, 55,101389 5. Chowhan, A.et al. J. Biol. Macromol. 2020, 150, 559–572. 6. Wu, Y.et al.J. Asian J. Pharm. Sci. 2019, 14, 1–15.

2024-12-04

·药明康德

罗氏超9亿美元囊获潜在“first-in-class”自身免疫疗法！

▎药明康德内容团队编辑 COUR Pharmaceuticals今日宣布与罗氏（Roche）旗下基因泰克（Genentech）达成战略合作与许可协议，双方将共同开发和商业化COUR的专有免疫耐受纳米颗粒（tolerogenic nanoparticle）疗法，用于治疗自身免疫性疾病。 COUR是一家处于临床阶段的生物技术公司，致力于开发治疗自身免疫性和炎症性疾病的疗法。COUR的潜在“first-in-class”疗法基于其专有的抗原特异性免疫耐受平台，旨在对免疫系统进行重新编程，以解决免疫介导疾病的根本原因。来自多个临床和临床前项目的数据表明，COUR的候选产品能够诱导抗原特异性免疫耐受，具有治疗多种自身免疫性和炎症性疾病的潜力。目前，COUR正在开展一项针对重症肌无力的1b/2a期双盲、安慰剂对照、多中心临床试验，同时推进针对1型糖尿病的候选药物开发。此外，公司已完成乳糜泻（与武田合作）和原发性胆汁性胆管炎的首次人体试验。图片来源：123RF 根据协议条款，COUR将获得4000万美元的预付款和近期里程碑付款，此外，还可获得超过9亿美元的开发、商业化和销售里程碑款项。根据合作协议，COUR负责完成前期临床开发和生产技术转移，而基因泰克将承担临床开发、监管申报及商业化的相关工作。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] COUR Pharmaceuticals Enters Collaboration and Licensing Agreement with Genentech to Develop and Commercialize Tolerogenic Therapy for the Treatment of an Autoimmune Disease. Retrieved December 3, 2024 from https://www.globenewswire.com/news-release/2024/12/03/2990410/0/en/COUR-Pharmaceuticals-Enters-Collaboration-and-Licensing-Agreement-with-Genentech-to-Develop-and-Commercialize-Tolerogenic-Therapy-for-the-Treatment-of-an-Autoimmune-Disease.html 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

引进/卖出免疫疗法

2024-11-28

·乐威医药

政策发布丨关于同意北京等十省（市）开展优化药品补充申请审评审批程序改革试点的批复

政策发布 POLICY RELEASE 乐威医药：坚持用化学改变世界国家药监局关于同意北京等十省（市）开展优化药品补充申请审评审批程序改革试点的批复北京、天津、河北、上海、江苏、浙江、山东、广东、重庆、四川省（市）药品监督管理局：你们关于申请优化药品补充申请审评审批程序改革试点的请示收悉。经研究，现批复如下: 同意你们开展优化药品补充申请审评审批程序改革试点，请严格按照《国家药监局关于印发优化药品补充申请审评审批程序改革试点工作方案的通知》（国药监药注〔2024〕10号）要求，组织开展试点工作。国家药监局 2024年11月22日版权声明：本文内容及图片，如有侵权请联系删除。免责声明：本文内容仅作信息交流学习，并不反映任何意见及观点。往期推荐乐威医药（欧洲）分公司正式成立乐威医药沧州GMP生产基地高活生产线启用乐威医药亮相意大利CPHI Milan 2024

100 项与美喹他嗪相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01324	美喹他嗪	R06AD07	DB01071

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
变应性结膜炎	新西兰	-	1999-07-09
哮喘	日本	Asahi Kasei Corp.	1990-03-30
哮喘	日本	Alfresa Pharma Corp.	1990-03-30
皮炎	日本	Asahi Kasei Corp.	1982-10-07
湿疹	日本	Asahi Kasei Corp.	1982-10-07
瘙痒	日本	Asahi Kasei Corp.	1982-10-07
瘙痒	日本	Alfresa Pharma Corp.	1982-10-07
过敏性鼻炎	日本	Asahi Kasei Corp.	1982-10-07
过敏性鼻炎	日本	Alfresa Pharma Corp.	1982-10-07
荨麻疹	日本	Asahi Kasei Corp.	1982-10-07
荨麻疹	日本	Alfresa Pharma Corp.	1982-10-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00880607 (CTgov)	临床4期	脊柱融合 \| 术后疼痛 \| 脊柱侧凸 ... 更多	84	Intrathecal morphine	衊鹽鑰觸鬱窪窪範遞憲(遞蓋鹽鹽壓網網鹽夢製) = 艱遞顧齋齋製選構餘鑰鹹廠鑰觸齋膚齋衊廠衊 (淵簾襯願觸觸糧選壓網, 選繭願壓獵範壓鏇遞積 ~ 選襯鹽鹽網餘網遞壓膚) 更多	-	2020-04-22
NCT00934661 (CTgov)	临床4期	-	40	Extended Release Epidural Morphine (EREM) (Extended Release Epidural Morphine)	製顧觸淵獵繭艱窪鏇網(餘遞鏇衊範選鬱膚繭範) = 觸遞觸鏇鑰鑰觸築憲鏇鏇願艱獵膚齋觸淵廠醖 (積鬱淵遞襯鹹積齋簾遞, 1.29) 更多	-	2018-01-16
				Placebo (Placebo Group)	製顧觸淵獵繭艱窪鏇網(餘遞鏇衊範選鬱膚繭範) = 糧醖糧製蓋築鏇獵淵簾鏇願艱獵膚齋觸淵廠醖 (積鬱淵遞襯鹹積齋簾遞, 2.02) 更多
EAN2016	临床3期	多发性硬化症一线	-	Delayed-release dimethyl fumarate (DMF)	鏇獵願壓膚衊餘壓鹽簾(艱壓艱鑰願繭製願選簾): rate ratio = 0.76 (95% CI, 0.57 ~ 1.0), P-Value = 0.0474	积极	2016-06-23
				Glatiramer acetate (GA)
PA022 (AAO2015)	临床2期	青光眼	20	ENV515 Travoprost XR intracameral implant	餘醖選網鏇顧憲醖衊獵(窪壓構鹽餘鏇觸餘糧範) = no adverse events 襯網鏇範獵餘廠齋廠願 (選鑰夢齋齋蓋製鏇範壓 )	-	2015-11-15